, Volume 7, Issue 1, pp 71–78 | Cite as

Tissue distribution and cellular distribution of liposomes encapsulating muramyltripeptide phosphatidyl ethanolamide

Tissue and cellular distribution of LE-MTPPE
  • P. M. B. Melissen
  • W. van Vianen
  • P. J. M. Leenen
  • I. A. J. M. Bakker-Woudenberg


In previous studies it was shown that administration of liposome-encapsulated MTPPE (LE-MTPPE) led to resistance againstKlebsiella pneumoniae infection. To get more insight in the cell types that are involved in this by LE-MTPPE induced antibacterial resistance, the tissue distribution of liposomes encapsulating MTPPE and the distribution over the cells in the main target organs were investigated. After intravenous injection of the liposomes in mice a substantial amount was recovered from liver and spleen and a smaller amount from the lung. In the liver 83% of the liposomes was taken up by the macrophages. In the spleen also most liposomes were taken up by macrophages of the red and white pulp as well as by dendrocytes. The liver and spleen were also the organs in which, after intravenous inoculation,K. pneumoniae was trapped. It was observed that cells containing LE-MTPPE often had not taken up bacteria. Most bacteria, about 73%, were found in cells not containing liposomes. The capacity of the liposome-containing cells to take up bacteria did not change with time. This suggests that the by LE-MTPPE immunostimulating effect is due to the production of cytokines by the cells that take up LE-MTPPE. These cytokines might stimulate other cells to the killing of bacteria.

Key words

Liposome-encapsulated MTPPE Macrophages Tissue Distribution 



liposome-encapsulated muramyl tripeptide


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Melissen PMB, Van Vianen W, Rijsbergen Y, Bakker-Woudenberg IAJM. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide in treatment of experimentalKlebsiella pneumoniae infection. Infect Immun 1992; 60: 95–101.PubMedGoogle Scholar
  2. 2.
    Melissen PMB, Van Vianen W, Bakker-Woudenberg IAJM. Roles of peripheral leukocytes and tissue macrophages in antibacterial resistance induced by free or liposome-encapsulated muramyl tripeptide phosphatidylethanolamide. Infect Immun 1992; 60: 4891–7.PubMedGoogle Scholar
  3. 3.
    Schumann G, Van Hoogevest P, Frankhauser P,et al. Comparison of free and liposomal MTP-PE: pharmacological, toxicological and pharmacokinetic aspects. In: Lopez-Berestein G, Fidler IJ, eds. Liposomes in the therapy of infectious diseases and cancer. New York: Alan R. Liss, Inc., 1989: 191–203.Google Scholar
  4. 4.
    Fidler IJ, Brown NO, Hart JR. Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously.J Biol Response Modif 1985; 4: 298–309.Google Scholar
  5. 5.
    Van Hoogevest P, Frankenhauser P. An industrial liposomal dosage form for muramyl-tripeptide-phosphatidyl ethanolamine (MTP-PE). In: Lopez-Berestein G, Fidler J, eds. Liposomes in the therapy of infectious diseases and cancer. New York: Alan R. Liss, Inc., 1989: 453–66.Google Scholar
  6. 6.
    Lopez-Berestein G. Liposomes in infectious diseases: present and future. Curr Clin Top Infect Dis 1989; 10: 241–53.PubMedGoogle Scholar
  7. 7.
    Swenson CE, Popescu MC, Ginsberg RS. Preparation and use of liposomes in the treatment of microbial infections. Crit Rev Microbiol 1988; 15: S1–29.PubMedGoogle Scholar
  8. 8.
    Dukor P, Schumann G. Modulation of non-specific resistance by MTP.PE. In: Majde JA, ed. Immunopharmacology of infectious diseases. Vaccine adjuvants and modulators of non-specific resistance of infectious diseases. New York: Alan R. Liss, Inc., 1987: 255–65.Google Scholar
  9. 9.
    Gangemi JD, Nachtigal M, Barnhart D, Krech L, Jani P. Therapeutic efficacy of liposome-encapsulated rib avirin and muramyl tripeptide in experimental infection with influenza or herpes simplex virus. J Infect Dis 1987; 55: 510–7.Google Scholar
  10. 10.
    Koff WC, Showalier SD, Hampar B, Fidler IJ. Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide. Science 1985; 228: 495–6.PubMedGoogle Scholar
  11. 11.
    Gabizon A, Huberty J, Straubinger RM, Price DC, Papahadjopoulos D. An improved method for in vivo tracing and imaging of liposomes using a gallium 67-deferoxamine complex. J Liposome Res 1988–89; 1: 123–35.Google Scholar
  12. 12.
    Leenen PJM, Melis M, Kraal G, Hoogeveen AT, Van Ewijk W. The monoclonal antibody ER BM DM 1 recognizes a macrophage and dendritic cell differentiation antigen with aminopeptidase activity. Eur J Immunol 1992; 22: 1567–72.PubMedGoogle Scholar
  13. 13.
    Heaton WA, Davis HH, Welch MJ,et al. Indium III; a new radio nuclide label for studying human platelet kinetics. Br J Heamatol 1979; 42: 613–22.Google Scholar
  14. 14.
    Bakker-Woudenberg IAJM, Lokerse AF, Vink JC, Roerdink FH, eds. Liposomes-encapsulated ampicillin or muramyl dipeptide againstListeria monocytogenes in vivo andin vitro. In:Liposomes in the therapy of infectious diseases and cancer. New York: Alan R. Liss, Inc., 1989: 275–85.Google Scholar
  15. 15.
    Phillips NC, Chedid L. Muramyl peptides and liposomes. In: Gregoriadis G, ed. Liposomes as drug carriers. New York: John Wiley & Sons Ltd, 1988: 243–59.Google Scholar
  16. 16.
    Daemen T, Veninga A, Roerdink FH, Scherphof GL. Endocytic and tumoricidal heterogenicity of rat liver macrophage subpopulations. Select Cancer Ther 1989; 5: 157–68.Google Scholar
  17. 17.
    Akahane K, Yamaguchi F, Kita Y, Une T, Osada Y. Stimulation of macrophages by muroctasin to produce colony-stimulating factors. Drug Res 1990; 40: 179–83.Google Scholar
  18. 18.
    Frost H, Murray JL, Chaudri HA, Van Damme J. Interleukin 6 induction by a muramyl tripeptide derivative in cancer patients. J Biol Response Modif 1990; 9: 160–6.Google Scholar
  19. 19.
    Sancéau J, Falcoff R, Beranger F, Carter DB, Wietzerbin J. Secretion of interleukin-6 (IL-6) by human monocytes stimulated by muramyl dipeptide and tumour necrosis factor alpha. Immunology 1990; 69: 52–6.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • P. M. B. Melissen
    • 1
  • W. van Vianen
    • 1
  • P. J. M. Leenen
    • 1
  • I. A. J. M. Bakker-Woudenberg
    • 1
  1. 1.Department of Clinical MicrobiologyErasmus University RotterdamDR Rotterdamthe Netherlands

Personalised recommendations